Novartis Is “On A Mission” To Address Unmet Hypertension Needs
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is targeting the 30 mil.-35 mil. untreated hypertension patients in the U.S. and is relaunching a compliance program to target existing patients.
You may also be interested in...
Novartis’ Diovan Growth Bolstered By Awareness Program, Part D
The company reported double-digit sales growth for its top three products in the second quarter.
Novartis’ Diovan Growth Bolstered By Awareness Program, Part D
The company reported double-digit sales growth for its top three products in the second quarter.
Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction
Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.